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ABSTRACT
Ewing sarcoma (ES) is an aggressive tumor defined by EWSR1 gene fusions 
that behave as an oncogene. Here we demonstrate that RING1B is highly expressed 
in primary ES tumors, and its expression is independent of the fusion oncogene. 
RING1B-depleted ES cells display an expression profile enriched in genes functionally 
involved in hematological development but RING1B depletion does not induce cellular 
differentiation. In ES cells, RING1B directly binds the SCN8A sodium channel promoter 
and its depletion results in enhanced Nav1.6 expression and function. The signaling 
pathway most significantly modulated by RING1B is NF-κB. RING1B depletion results 
in enhanced p105/p50 expression, which sensitizes ES cells to apoptosis by FGFR/
SHP2/STAT3 blockade. Reduced NaV1.6 function protects ES cells from apoptotic cell 
death by maintaining low NF-κB levels. Our findings identify RING1B as a trait of the 
cell-of-origin and provide a potential targetable vulnerability.
INTRODUCTION
Ewing sarcoma (ES) is an aggressive and poorly 
differentiated tumor, typically arising from bone and soft 
tissues in children and young adults. It is characterized by 
reciprocal translocations that result in almost all cases in 
the fusion of the EWS RNA binding protein 1 (EWSR1) to 
an ETS transcription factor, being EWSR1–FLI1 the most 
common chimera [1, 2]. ES tumors display a high degree 
of genomic stability with very few recurrent mutations 
besides the pathognomonic fusion, and are among the most 
genetically normal cancers [3–5]. This strikingly unaltered 
somatic landscape highlights the role of EWSR1-FLI1 as the 
unique trigger of the oncogenic transformation in an otherwise 
yet unidentified cell-of-origin harboring key features that will 
likely contribute to the eventual development of ES.
Meta-analysis of data coming from EWSR1-FLI1 gain-
of-function approaches revealed that the genes up-regulated 
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by the fusion in heterologous cell systems are more numerous 
and display more similarities among different experimental 
models than the genes down-regulated. Since the cell-of-
origin of ES remains elusive, gain-of-function models have 
been carried out expressing the oncogene in a variety of 
poorly or undifferentiated heterologous cell types. Genome-
wide analysis using high-throughput sequencing technologies 
have identified a plethora of EWSR1-FLI1 direct targets 
and shown that EWSR1-FLI1 primarily up-regulates gene 
expression through the interaction with GGAA repeats 
present in satellite DNA within the genome [6]. In contrast, 
data obtained by depleting EWSR1-FLI1 in ES cells revealed 
that many more genes resulted down-regulated by the fusion 
oncogene than up-regulated, suggesting that gene repression 
may be more prevalent than transcriptional activation [7]. 
However, many of these EWSR1-FLI1 repressed targets are 
divergent and highly dependent on the cellular background 
[8]. Since EWSR1-FLI1 directly binds to promoters of a 
small subset of repressed targets [7], the lack of consistency 
among the different sets of repressed genes is likely due to 
a variety of both direct and indirect mechanisms used by 
EWSR1-FLI1 for gene silencing.
EZH2 is a direct EWSR1-FLI1 target that belongs 
to the Polycomb (PcG) family of epigenetic regulators and 
blocks endothelial and neuro-ectodermal differentiation of ES 
cells [9]. PcG proteins form two major families of complexes, 
the Polycomb-repressive complex (PRC) 1 and 2. PRC2 
comprises EED, SUZ12 and EZH2, which catalyzes the 
K27 trimethylation of histone H3 (H3K27me3). Mammalian 
PRC1 includes BMI1, MEL18, and RING1B, which 
catalyzes H2A K119 ubiquitination (ubH2K119) [10, 11]. 
PRC1 and PRC2 mostly differ in their genomic localization 
with a small subset of PRC1 co-localizing with H3K27me3. 
Adding complexity, six major groups of PRC1 subcomplexes 
with specific developmental functions and mutually exclusive 
PRC1 subunits have been described, being RING1B the 
unique common feature [12]. Importantly, it has recently 
been reported that RING1B catalytic activity results in gene 
repression, consistent with the classic repressive function 
of the Polycomb complexes, whereas catalytic-independent 
association of RING1B with UTX, an H3K27 demethylase, 
and p300, leads to transcriptional activation [13].
Despite the important role of the epigenetic 
landscape in ES, studies addressing the PcG contribution 
to ES tumorigenesis have been restricted to EZH2 and 
BMI1. Here we investigate the expression and function of 
RING1B in ES, a protein with unique abilities among the 
PcG family of epigenetic regulators.
RESULTS
Ewing sarcoma tumors express high levels of 
RING1B
ES tumors express high EZH2 mRNA levels [9]. 
To better characterize PcG expression we analyzed EZH2 
and RING1B protein expression in ES primary tumors. 
EZH2 was detected in all the tumor samples, most of 
them with variable EZH2 expression patterns (Figure 
1, right). Particularly poor EZH2 expression was found 
in largely hemorrhagic tumors, blood clots and tumors 
infiltrating the adipose tissue (Figure 1, J-N). In contrast, 
RING1B was highly expressed and uniformly distributed 
throughout the tumor in most samples, reaching the 
maximum score (Figure 1, left; Supplementary Figure 
S1A). Of note, RING1B was expressed in endothelial 
cells of tumor blood vessels and in the adipose tissue 
(Figure 1C, 1G), whereas RING1B expression was 
observed in sparse cells of blood clots (Figure 1F). In 
these tissues EZH2 expression was low. Importantly, 
RING1B expression in ES was found to be significantly 
higher than in other developmental tumors such as 
rhabdomyosarcoma, synovial sarcoma and Wilms tumor 
(Supplementary Figure S1B).
Since it has been postulated that neural crest-
derived progenitors could be the cell-of-origin [14] and 
ES tumors display a continuum of different degrees of 
neural differentiation [15], RING1B expression was 
also investigated in neural tissues. Moderate RING1B 
expression was found in cerebellum and peripheral 
sympathetic ganglia, whereas low or no expression was 
found in the brain and spinal cord (Supplementary Figure 
S1C). In addition, RING1B could not be detected in 
undifferentiated neuroblastic aggregates of the normal 
fetal adrenal medulla, a derivative of the embryonic neural 
crest (Supplementary Figure S1C).
Next we analysed the expression of BMI1 
and MEL18, two PRC1 proteins. Some specimens 
displayed low BMI1 and MEL18 levels (Supplementary 
Figure S2A and S2B), accordingly to reported BMI1 
expression in many, but not all, ES primary tumors [16]. 
In embryonic neural tissues BMI1 expression pattern 
resembled that of RING1B, with low to moderate 
expression in most of the embryonic neural tissues 
(Supplementary Figure S2C).
RING1B expression is independent of EWSR1-
FLI1
To test whether RING1B expression was modulated 
by the oncogene, EWSR1-FLI1 was introduced 
in 293T and HeLa cells. In both cell lines EZH2 
expression was enhanced, as previously reported [9], 
whereas RING1B levels were not affected (Figure 2A). 
Conversely, down-regulation of EWSR1-FLI1 in A673 
cells resulted in diminished EZH2 levels, but RING1B 
levels remained unaffected (Figure 2B). Accordingly, 
endogenous EWSR1-FLI1 binds specifically to a 
conserved ETS recognition sequence of the EZH2 
promoter [17]. In contrast, the genomic region of 
RING1B was not reported to be an EWSR1-FLI1-
direct binding domain [6, 18] nor RING1B was a 
Oncotarget3www.impactjournals.com/oncotarget
Figure 1: RING1B and EZH2 expression in primary Ewing sarcoma (ES) tumors. Immunohistochemistry analysis of 
RING1B (A-G) and EZH2 (H-N) expression in serial sections of primary ES tumors. Right columns, higher magnifications of the left panel 
fields (scale bars 50μm). A, B, H, I. samples with intense and homogeneous RING1B and EZH2 staining; C, D, E, J, K, L. hemorrhagic 
samples with intense RING1B and low EZH2 staining. Blood lakes can be extensively observed in these tumors; F, M. blood clots in an ES 
sample; G, N. adipose tissue in an ES sample.
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differentially expressed gene in EWSR1-FLI1-depleted 
cells [19, 20]. We suspected that EWSR1-FLI1-
independency of RING1B expression might be reflecting 
the high levels of expression of the cell-of-origin where 
the oncogenic translocation occur, likely regulating key 
functions of this cell. Therefore, we decided to study 
the role of RING1B in ES cells by depleting RING1B 
protein levels.
Gene expression profile in RING1B-depleted ES 
cells is unique and enriched in genes functionally 
involved in hematological development
To identify genes whose expression is regulated 
by RING1B in ES tumors we analyzed four different ES 
cell lines stably depleted of RING1B by short hairpin 
RNA (shRNA) (Figure 3A). Gene expression analysis 
Figure 2: RING1B expression is independent of EWSR1-FLI1. A. EWSR1-FLI1 was ectopically expressed in 293T (left panel) 
and HeLa (right panel) cells and RING1B and EZH2 levels were determined by western blot. Actin and Tubulin, loading controls. B. A673 
cells were transiently transfected with mock or FLI1 short interfering RNA (siRNA) and RING1B and EZH2 levels were determined 48 
hours later by western blot (left panel) and qRT-PCR (right panel). Numbers at the bottom represent protein band intensities normalized to 
Actin and relative to control cells, as described in “Methods”. Graph shows mean ± SD of three replicate samples from one representative 
experiment out of three.
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Figure 3: Characterization of the transcriptome in RING1B-depleted ES cells. A. Efficiency of stable Ring1B knockdown 
(short hairpin, sh) in ES cells determined by qRT-PCR (left panel) and western blot (right panel). *, P < 0.05; **, P < 0.01; ***, P < 0.005. 
Numbers at the bottom, RING1B expression normalized to Lamin B and relative to RING1B levels in each control cell line. B. Cluster 
dendrogram derived from array expression data of the four ES parental cell lines (left panel) and functions of the genes differentially 
regulated in the A4573 cell line versus A673/SK-ES-1/TC-1 cell lines, identified by the Ingenuity Pathway Analysis (IPA) software (right 
panel). C. Primary heat map of genes differentially expressed between shMock and shRING1B cells. Right panel, heat map depicting the 
first 30 annotated and up-regulated genes in shRING1B cells. D. Top functional annotations enriched among RING1B-regulated genes, 
identified by IPA software. Array data deposited at the Gene Expression Omnibus (GEO, National Center for Biotechnology Information) 
with accession number GSE71007.
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followed by unsupervised hierarchical clustering of the 
most variably expressed genes stratified parental cell lines 
into one main group formed by A673, SK-ES-1 and TC71 
and segregated the A4573 cell line (Figure 3B). Of note, 
A4573 cells also display low BMI1 protein levels [21].
Despite substantial differences in A4573 gene 
expression profile, linear models for microarrays 
(LIMMA) analysis was performed using the four cell 
line data in an attempt to identify common traits of 
RING1B gene regulation in ES. Logarithmic fold change 
for each shRING1B/shMock sample pair revealed that 
RING1B depletion resulted in altered expression of 1430 
sequences (Figure 3C). Among them, 523 corresponded to 
annotated genes, 259 up-regulated (49%) and 264 down-
regulated (51%), a ratio that parallels that of RING1B-
transcriptionally regulated genes in melanoma [13]. The 
genes differentially expressed in RING1B-depleted cells 
were then analyzed at the functional level using the IPA 
software. This analysis revealed “tissue morphology” 
and “hematological system development and function” 
as the top two biological functions altered, while the 
top canonical pathways identified included “heme 
biosynthesis” and “haematopoiesis from pluripotent stem 
cells” (Figure 3D).
To compare RING1B with other PcG proteins, 
BMI1 was depleted in A673 and TC71 cells 
(Supplementary Figure S3A). Gene expression analysis 
revealed that BMI1 or RING1B depletion resulted in 734 
and 838 differentially expressed sequences, respectively 
(Supplementary Figure S3B), 196 overlapping, and among 
these, 70 were annotated sequences (Supplementary 
Figure S3C). Most genes, however, were differentially 
regulated by each PRC1 protein in ES cells.
EZH2 downregulation in ES cells results in the 
induction of genes important for neural and endothelial 
differentiation [9]. In contrast, few endothelial and neural 
genes were identified among the annotated transcripts 
in RING1B-depleted cells (Figure 4A). Furthermore, 
RING1B depletion only resulted in enhanced expression 
of three genes, MS4A3, CDRT1 and TLE4, out of the 
most significantly EZH2 downregulated genes in ES cells 
[9] (Figures S4, S5).
All-trans retinoic acid (ATRA)-induced neural stem 
cell differentiation results in EZH2 down-regulation and 
decreased binding of EZH2 to ATRA-inducible target 
genes [22]. Particularly important for ES biology is the 
differentiation blockade that EZH2 imposes in ES cells, 
which can undergo neuroectodermal differentiation 
with butylated hydroxyanisole (BHA) only upon EZH2 
depletion [9]. ATRA and BHA treatment of SK-ES-1 cells 
resulted in reduced EZH2, but not RING1B, mRNA levels 
(Figure 4B). Furthermore, neither ATRA nor BHA were 
able to induce differentiation in shRING1B cells since 
mRNA levels of neural and endothelial differentiation 
genes remained similar to those of the untreated cells 
(Figure 4C).
RING1B regulates the NaV1.6 sodium channel in 
Ewing sarcoma cells
FGF14 and SCN8A were among the top 
30-upregulated annotated sequences upon RING1B 
depletion (Figure 3C), and these increases where validated 
by qRT-PCR in RING1B-depleted cells (Figures 5A, 
S6A). SCN8A encodes the α subunit of the voltage-gated 
sodium channel type VIII, or NaV1.6. This protein forms 
a sodium-selective channel essential for rapid membrane 
depolarization in response to voltage differences in 
excitable neurons. FGF14 is a member of the intracellular 
fibroblast growth factor subfamily (iFGF) that co-localizes 
and interacts with the NaV channel α subunits, being 
NaV1.6 the most sensitive to FGF14 modulation [23]. 
While RING1B was not detected at the FGF14 promoter 
(data not shown), it was found to bind to the promoter 
region of the SCN8A gene in ES cells (Figure 5B). 
RING1B depletion using an independent shRNA construct 
[11] confirmed that SCN8A is repressed by RING1B in 
ES cells (Supplementary Figure S6B). SCN8A released 
expression in RING1B-depleted cells resulted in 
enhanced NaV1.6 protein levels (Figure 5C). In contrast, 
RING1B depletion in 293T did not affect NaV1.6 levels 
(Figure 5C) while in neuroblastoma SK-N-SH cells caused 
subtle increases in SCN8A mRNA levels (Figures S6C), 
suggesting that RING1B regulation of the NaV1.6 channel 
is specific of ES cells.
Next we investigated NaV1.6 channel regulation 
by other PcG proteins. BMI1 depletion resulted in 
SCN8A down-regulation while EZH2 depletion lead to 
minor changes in SCN8A mRNA levels (Supplementary 
Figure S7). Furthermore, treatment with the histone 
methylation inhibitor DZNep did not affect SCN8A 
mRNA levels (Supplementary Figure S7D). All these 
data suggest that NaV1.6 channel repression in ES is 
specifically set by RING1B.
To check the functional impact of the enhanced 
expression of NaV1.6 upon RIING1B depletion we 
used the voltage-clamp technique in the whole-cell 
configuration to record voltage-gated sodium currents. 
In response to depolarizing pulses, significant fast-
activating and fast-inactivating inward sodium currents, 
with a persistent component (consistent with NaV1.6 
electrophysiological properties [24, 25]), were only 
recorded in shRING1B cells but not in shMock control 
cells (Figure 5D). Since NaV1.6 knockout in dorsal-
root ganglion cells results in migration towards the 
ventral region and acquisition of a parasympathetic 
phenotype [26] we investigated the migratory abilities 
of ES cells. A4573 and A673 control cells displayed 
migratory abilities that were attenuated in RING1B 
depleted cells (Figure 5E). Since RING1B depletion 
affects the expression of very few neural genes and did 
not alleviate ES cells from their neural differentiation 
blockade, this result suggests that targeted NaV1.6 
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repression might be of particular relevance for ES 
biology.
RING1B modulates the NF-κB pathway in 
Ewing sarcoma cells
To identify molecular pathways affected by 
RING1B-modulated targets we conducted IPA. On the 
basis of the four RING1B-depleted cell line signature, 
the IPA analysis revealed NF-κB as the most significantly 
altered node (Figure 6A). To explore this pathway we 
performed western blot analyses of the five members 
of the NF-κB transcription factor family: NF-κB1 (p50 
and its precursor p105), NF-κB2 (p52 and its precursor 
p100), c-Rel, RelA/p65 and RelB. Levels of p105 and p50 
were enhanced to variable degrees in shRING1B cells 
when compared to their corresponding shMock controls 
(Figure 6B). RING1B depletion using an independent 
Figure 4: RING1B depletion does not result in global alterations of developmental transcription programs in ES cells. 
A. Heat map showing endothelial (red) and neural (black) genes up-regulated in RING1B-depleted cells, identified by manual curation 
of the microarray annotated sequences. B. RING1B and EZH2 mRNA levels determined by qRT-PCR in SK-ES-1 cells treated with 
differentiating agent butylated hydroxyanisole (BHA) and all trans-retinoic acid (ATRA). C. SK-ES-1 cells, either shMock or shRING1B, 
were treated with BHA or ATRA and mRNA levels of different neural or endothelial genes were analyzed by qRT-PCR. B and C. graphs 
show mean ± SD from two independent experiments performed with three replicate samples.
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Figure 5: RING1B represses the NaV1.6 channel in ES cells. A. SCN8A mRNA levels in RING1B-depleted cells determined by 
qRT-PCR and referred to shMock control mRNA levels. *, P < 0.05; **, P < 0.01. B. Relative enrichment of RING1B occupancy at SCN8A 
promoter, measured by ChIP-qPCR. Graph displays percentage of RING1B recruitment to two different SCN8A promoter amplicons, 
referred to enrichment from the IgG control, set as 1. Data express mean ± SD of three independent experiments. *, P < 0.05; **, P < 0.01. 
C. NaV1.6 protein levels in cytoplasmic (A4573) and total (A673, SK-ES-1, TC-71, 293T) extracts from control or RING1B-depleted 
cells, analyzed by immunoblot. Numbers at the bottom, band intensities normalized to Actin or Lamin B and relative to control cells. D. 
Representative current traces obtained from shMock and shRING1B SK-ES-1 cells clamped at -90 mV and pulsed for 40 ms to the indicated 
depolarizing voltage (top) and average current density-voltage (I-V) relationships for shMock (open circles, n = 5) and shRING1B (filled 
cyan circles, n = 5) cells (bottom). Fast-activating inward currents with both transient and persistent components, consistent with NaV1.6 
currents, were only observed in shRING1B SK-ES-1 cells (peak current was 4.2 ± 0.4 pA/pF) and the corresponding V1/2 act, kact and 
Vrev values after fitting the I-V curve to a Boltzmann equation (see Methods for further details) were (in mV): -21 ± 4.1 mV (as reported 
for NaV1.6 channels heterologous expression in the ND7/23 neuronal cells, either in the absence or presence of FGF14 (54;61)), 10.8 ± 
2.1 and 84.5 ± 16.3, respectively. E. Cell migration speed measurements (in micron/sec) during wound healing from shMock (open) and 
shRING1B (black filled) A4573 and A673 cell lines (obtained in three different experiments). Symbols represent individual cells. Red bars 
depict mean ± SEM speed. Suppressing RING1B expression, which correlates with increased SCN8A expression, decreased cell speed in 
A4573 and A673 cells. **, P<0.01; ***, P<0.001.
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Figure 6: RING1B represses NF-κB in ES cells. A. Top-scoring multigene network associated by the IPA software to microarray 
expression data in RING1B-depleted cells. Overexpressed genes, red; downregulated genes, green. B. Levels of NF-κB proteins, detected 
by immunoblot performed using total extracts of shMock and shRING1B cells. Numbers at the bottom, band intensities normalized to Actin 
and relative to their own control cells. C. Flow cytometry analysis of A673 cells treated with 25 μM SU5402 or 50 μM NSC87877 for 24h. 
Percentage of cells in the sub-G1 region is indicated. DNA histograms of 10,000 propidium iodide stained cells.
Oncotarget10www.impactjournals.com/oncotarget
shRING1B also resulted in consistently enhanced p50 
levels (Supplementary Figure S8A). RING1B-depletion 
in non-ES cells like 293T and SK-N-AS (neuroblastoma) 
displayed inconsistent changes in NF-κB1 levels 
(Supplementary Figure S8C).
Since the NF-κB pathway is a regulator of stress 
response, next we checked the sensitivity of ES cells to 
challenging conditions. A673 cells were subjected to a 
panel of chemical inhibitors and cell viability was tested 
by flow cytometry using propidium iodide staining. Two 
drugs induced significant apoptotic cell death: SU5402 
and NSC87877. Whereas SU5402 irreversibly blocks 
FGF and VEGF tyrosine kinase receptors [27], NSC87877 
specifically inhibits SHP2 [28], a tyrosine phosphatase that 
participates in the regulation of FGFR signalling [29]. 
Interestingly, RING1B-depleted cells treated with these 
inhibitors showed enhanced sub-G1 peaks when compared 
to shMock cells (Figure 6C). To better characterize this 
effect, the four ES cell lines, either shMock or shRING1B, 
were treated with the two inhibitors. NF-κB1 levels in 
shRING1B cells remained elevated compared to their 
own shMock controls regardless of the inhibitor treatment 
(Supplementary Figure S8B). SU5402 and NSC87877 
treatments resulted in enhanced cleaved PARP1 levels in 
shRING1B cells when compared to controls (Figure 7A), 
indicating that RING1B depletion sensitizes ES cells 
to the apoptosis induced by the FGFR-SHP2 blockade. 
In contrast, RING1B depletion in 293T and SK-N-AS 
cells did not affect cleaved PARP levels (Figure 7B). 
IκB kinase (IKK) α/β inhibition with BMS-345541 
attenuated SU5402-induced PARP1 cleavage in A673 
shRING1B cells, further suggesting that NF-κB is pivotal 
for RING1B-mediated sensitivity to apoptosis in ES cells 
(Figure 7C).
Activation of FGFRs results in the stimulation of 
several signaling pathways including STAT3. Therefore, 
we investigated the sensitivity of ES cells to the STAT3 
inhibitor S31-201. As shown in Figure 7D, ES cells 
viability was affected at significantly lower concentrations 
of S31-201 than 293T cells. RING1B depletion further 
sensitized ES cells to S3I-201, as shown by the appearance 
of cleaved PARP1 at lower inhibitory concentrations 
compared to control cells (Figure 7E).
Increases in intracellular sodium through voltage 
sensitive sodium channels can contribute to apoptotic 
cell death [30]. Therefore we asked whether the enhanced 
NaV1.6 functionality in RING1B depleted cells increased 
the sensitivity of ES cells to apoptosis by selective 
blocking of the voltage-sensitive sodium channel with 
Tetrodotoxin (TTX). A673 shRING1B cells treated with 
SU5402, NSC87877 or S31-201 and cultured in the 
presence of TTX showed decreases in p105 and p50 levels 
and lower cleaved PARP levels than cells cultured in the 
absence of TTX, suggesting that RING1B repression of 
NaV1.6 also contributes to protect ES cells from apoptotic 
cell death by maintaining low NF-κB levels (Figure 7F).
DISCUSSION
Recent next-generation sequencing studies have 
revealed the simplicity of the ES genome [1, 3-5] 
highlighting the critical importance of the EWSR1–ETS 
fusion event. The mechanism by which EWSR1-FLI1 
contributes to tumorigenesis is complex since the fusion 
oncogene affects the cell in many different ways. The best 
known function of the EWSR1-FLI1 protein is that of an 
aberrant transcription factor. However, other EWSR1-
FLI1 properties including RNA binding, RNA splicing 
and protein-protein interactions are increasingly being 
recognized as fundamental to understand the plethora of 
effects induced by the fusion oncogene. Equally important 
has been the recognition of the critical role of the cellular 
context for EWSR1-FLI1 activity. In normal murine 
and human fibroblasts, EWSR1-FLI1 by itself does not 
transform cells; instead, it results in cell cycle arrest [31]. 
Related to this is the fact that it has been very difficult 
to establish an appropriate animal model by introduction 
of EWSR1-FLI1 chimeras, suggesting that EWSR1-
FLI1 is not sufficient to define the origin of ES. Finding 
universal features for a cell-of-origin to tolerate EWSR1-
ETS chimeras would be extremely helpful to understand 
ES tumorigenesis. Here, we show that RING1B is highly 
and universally expressed in primary ES tumors. We 
also show that RING1B expression is not a direct target 
of the fusion oncogene and that RING1B levels are not 
affected by chemically induced differentiation of ES cells. 
Furthermore, we demonstrate that RING1B regulates, 
independently of the fusion oncogene, critical pathways 
that may reflect the biology underlying the cell of origin.
Chromatin repressive complexes like the PcG 
protein complexes PRC1 and PRC2 are essential 
mediators of stemness and critical contributors to 
cancer pathogenesis by suppressing the expression of 
tumor-suppressor genes and developmental regulators 
in a context-dependent, cell-type-specific manner [32]. 
Our data show an intense and universal expression of 
RING1B in ES primary tumors, in contrast with other 
PRC proteins which are selectively expressed in some 
but not all ES tumoral cells. Indeed BMI1 expression 
is variable among both primary tumors and cell lines in 
our experience and in previously published studies [21] 
and EZH2 expression is heterogeneous in most of ES 
primary tumors. A particularly low EZH2 expression 
was found in hemorrhagic areas and blood lakes and in 
tumors infiltrating the adipose tissue. Blood lakes are a 
striking feature of ES first recognized by James Ewing, 
which led him to describe the tumor as an endothelioma 
[33]. Van der Schaft and colleagues described an abundant 
presence of blood lakes and vascular-like tube formations, 
suggesting a contribution of the blood lakes to circulation 
recalling vasculogenic mimicry [34], as had previously 
been described in melanoma [35]. The lower expression of 
EZH2 in the blood lakes in our study is consistent with the 
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Figure 7: RING1B down-regulation sensitizes ES cells to undergo NF-κB-mediated apoptosis induced by FGFR 
signaling blockade. A. Immunoblot detection of cleaved PARP1 in shMock and shRING1B cells treated with 25μM SU5402 or 50 μM 
NSC87877 for 24h. B. Immunoblot detection of cleaved PARP1 in 293T embryonic and SK-N-AS neuroblastoma cells, treated as above. 
Numbers at the bottom, band intensities normalized to Actin or Lamin B and relative to their own control cells. C. Immunoblot detection 
of NF-κB1 (p105 and processed form p50) and cleaved PARP1 in A673 shRING1B cells after 24h with or without 25μM SU5402 and 
the inhibitor of the IκB kinase (IKK)α/β BMS-345541 at 300nM. D. Half maximal inhibitory concentration (IC50) values for S31-201 in 
ES and 293T cells, measured after 72h treatment and expressed as mean ± SD (n=3). ANOVA-Bonferroni post-hoc test, *** <0.001. E. 
Cleaved PARP1 in shMock and shRING1B A673 cells, after 24h treatment with the STAT3 inhibitor S3I-201 at 25μM, 50μM and 100μM. 
F. Levels of the NF-κB subunits p105 and p50, and cleaved PARP1 in shRING1B A673 cells, after 24h treatment with 25μM SU5402, 50 
μM NSC87877 or S3I-201 at 50μM in the absence or the presence of 1μM Tetrodotoxin (TTX).
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inhibitory function of EZH2 on endothelial differentiation 
[9]. In these cells RING1B retains a relatively high level 
of expression suggesting that RING1B could be important 
in an endothelial cell context. In this regard, it is notable 
that NF-κB has been shown to be crucial for endothelial 
cell fate determination and that NF-κB activation results 
in apoptosis in endothelial cells [36]. Similarly, we here 
report that, in shRING1B ES cells, enhanced NF-κB levels 
are detrimental and sensitize ES cells to apoptosis. Our 
results also help to explain previous studies reporting 
very low NF-κB activity in ES [37–39] and suggest that 
NF-κB is to be repressed in the ES cell-of-origin because 
elevated NF-κB levels in such cells result in apoptosis. 
According to our data, the ES cell-of-origin displays traits 
of endothelial-precursor cell biology.
FGF receptors (FGFRs) include a family of high- 
and low-affinity bFGF receptors. bFGF, a ubiquitously 
expressed growth factor that affects a broad spectrum of 
developmentally regulated cellular responses, induces cell 
death in ES [40]. Since bFGF has a critical role in the 
commitment of primitive neural cells toward a neuronal 
phenotype, the induction of apoptosis in ES was thought to 
be consistent with the hypothesis that Ewing tumors arise 
in a primitive neural stem cell. However, the magnitude of 
bFGF-induced cell death was heterogeneous suggesting 
that ES can arise from primitive cells at various stages 
and that the expression of different growth factors and 
hormones by Ewing tumors may modulate the effect of 
bFGF [41]. Our results suggest that RING1B regulates the 
apoptotic response of FGFR activation in ES cells and thus 
it could be the modulator element proposed in previous 
publications between extracellular signaling (hormones 
and growth factors) and cell type response. More recently, 
the FGF/FGFR signaling has been found to play a vital 
role in the development and maintenance of bone growth 
at growth plates [42]. Since we provide evidence of an 
active FGF/SHP2/STAT3 pathway in the potential Ewing 
cell-of-origin, a putative relationship with normal bone 
growth and development deserves further investigation.
STAT3 is known to drive pathways regulating 
normal cell growth, which result in tumorigenesis when 
deregulated [43]. Reportedly, 50% of ES primary tumors 
express activated/phosphorylated STAT3 [44, 45] and 
germline mutations of Protein tyrosine phosphatase delta 
(PTPRD, a STAT3 phosphatase) have recently been 
described in three ES patients [46]. Aberrant activation of 
STAT3 signaling participates in the initiation, development 
and progression of human cancers via induction of STAT3 
downstream genes that encode antiapoptotic proteins, cell 
cycle regulators and angiogenic factors such as Bcl-2, 
Cyclin D1 and VEGF [47]. Also, increased macrophage 
infiltration and tumor microvascular density have been 
noted in tumors from ES patients with poor prognoses and 
tumor associated macrophages are known to express high 
concentrations of cytokines that lead to aberrant activation 
of the JAK/STAT3 pathway. In addition, EWSR1-FLI1 
inhibition in ES cells resulted in the secretion of soluble 
factors, such as IL6, that activate STAT3 in bystander 
(non-targeted) ES cells, protecting them against apoptosis 
[48]. Since NF-κB modulates the expression of a variety 
of cytokines, release of NF-κB inhibition upon RING1B 
knockdown could result in a feed forward loop of STAT3 
activation and cytokine production. This adaptive response 
suggested that combination therapy with STAT3 inhibitors 
may increase the efficacy of targeted therapeutics in ES. 
Reports on JAK/STAT3 inhibitors have shown in vitro 
and in vivo activity against ES. For instance, Thiele et 
al. have shown the antitumoral activity of the JAK1/2 
inhibitor AZD1480 blocking endogenous constitutive 
and cytokine-induced activation of STAT3 in vitro and 
suppressing the growth of ES xenografts in vivo [49]. Our 
results showing higher sensitivity to STAT3 inhibition in 
RING1B-depleted cells suggest that combined inhibition 
of RING1B and STAT3 could generate enhanced 
antitumor effects against ES (proposed model in Figure 8). 
Inhibition of STAT3 activity is well-known to enhance 
chemosensitivity of multiple tumor types to a number 
of different cytotoxic agents or other targeted agents; 
therefore multiple combinations of target inhibition of 
key pathways for ES like RING1B and STAT3 together 
with conventional chemotherapy could represent a novel 
approach for ES patients.
The role of PcG increasing the chances for the cancer 
cell to survive in hostile microenvironments has recently 
been shown in ES and other tumors by Lawlor et al. [50]. 
They described KCNA5 repression by BMI1, and the 
impairment in the execution of hypoxia-induced apoptotic 
cell death. In this study we show that NaV1.6 regulation in 
ES is specific to RING1B, not being shared with other PcG 
proteins. RING1B represses the expression and function of 
this sodium channel, normally expressed in central neurons, 
dorsal root ganglia, peripheral neurons, heart, and glial cells. 
The selectivity of this regulation by RING1B is striking 
because many other neural genes are actively induced by 
the EWSR1-ETS fusion, globally resulting in a neural-like 
phenotype of the ES cell. Together with the well-known 
migration blockade caused by EWSR1-FLI1 in the chicken 
model [51] and our results would suggest co-regulation of 
the cellular migratory properties of ES cells by RING1B 
and the fusion oncogene.
The origin of ES has been an enigma since the first 
case was reported in 1921 [33]. Primitive neural crest 
cells, hematopoietic cells, and muscle cells as well as 
mesenchymal stem cells (MSC) have been considered 
possible cells of origin [52, 53]. Histologically, ES has a 
certain resemblance to primitive neuroectodermal cells 
[54]. Early neural markers are present in some tumors and 
ultrastructural features of neural cells can also be observed 
in some cases [15, 55, 56]. Furthermore, ES cells can be 
induced to differentiate in the laboratory towards the neural 
lineage [57]. Conversely, introduction of EWSR1-FLI1 into 
neuroblastoma cells has been shown to make the cells acquire 
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characteristics of ES [58]. EWSR1-FLI1 has been shown to 
induce neuroectodermal differentiation and up-regulate a 
number of genes associated with early neural differentiation 
[59]. Altogether, these findings raise the possibility that the 
neuroectodermal characteristics of the ES cell might be a 
direct result of EWSR1-FLI1 expression and not necessarily 
reflect a feature of the cell-of-origin.
An alternative hypothesis is that ES derives from a 
MSC. Although cranial bones develop from mesenchymal 
condensation of neuroectoderm [52], the long bones of the 
limbs originate from mesoderm [60] and there may not 
normally be primitive neuroectodermal cells in that bone. 
However, bone marrow mesenchymal cells can exhibit 
some characteristics of neuroectodermal cells [61, 62]. 
Figure 8: Proposed model for RING1B-dependent antiapoptotic function in ES. A. According to our results we propose 
an endothelial linage of the ES cell-of-origin where bFGF/VEGF are specially active and, upon binding to their receptors, activate a 
signaling cascade that transmits a nuclear signal prompting target genes to activate cell growth. As reporter for an endothelial progenitor 
cell (EPC) characteristic biology, proapoptotic genes remain inactive in cells with low NF-κB levels tightly controlled by RING1B in ES 
cells. B. Similar to EPC when treated with antiangiogenic factors, RING1B depletion in ES cells results in NF-κB activation, which binds 
to proapoptotic gene promoters and/or displaces transcription factors from prosurvival gene promoters. In this situation ES cells are highly 
sensitive to FGF/SHP2/STAT3 blockade (adapted from [36]).
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These cells can also be induced in vitro to differentiate 
towards the neural lineage [63, 64]. The term MSC usually 
implies a cell that has the capacity to differentiate towards 
various mesodermal lineages. Indeed, EWSR1-FLI1 
knockdown revealed that ES cells have some capacity for 
in vitro differentiation towards chondroblastic, osteoblastic 
and adipocytic lineages [53]. Furthermore EWSR1-FLI1 
expression in mesenchymal cells resulted in development 
of ES tumors [65, 66] and EWSR1-FLI1 introduction 
into a population of cells enriched for osteochondrogenic 
progenitors derived from the embryonic superficial zone of 
murine long bones revealed a subpopulation of precursor 
cells that further enhanced EWSR1-ETS–dependent tumor 
induction [67]. It is yet unclear whether there is a special 
subfraction of precursor cells that includes the cell of 
origin of ES, although Stamenkovic and colleagues have 
reported that primary ES tumors harbor a subpopulation 
of cells that express CD133 constituting 3-15% of tumor 
cells that display the plasticity, clonogenicity and tumor-
initiating capacity of tumor stem cells [68].
Murine studies have shown that the target cells 
of EWSR1-ETS might be cells of a narrow lineage of 
MSC and/or of a limited differentiation stage in support 
of a mesenchymal origin of ES. However, the simple 
knockdown of EWSR1-FLI1 in tumor cells does not 
cause them to revert to a normal mesenchymal cell. 
Constitutive expression of EWSR1-FLI1 protein in 
embryonic stem cells causes cell death [69], and mice 
with expression of EWSR1-FLI1 in the whole body have 
an embryonic lethal phenotype [70]. Target expression 
to bone marrow progenitor cells surprisingly produced 
leukemias [70]. EWSR1-FLI1 conditional expression in 
the mesoderm-derived tissues of the limbs resulted in limb 
shortening, muscle atrophy, osseous dysplasia and other 
developmental abnormalities [71]. However, sarcomas 
did not spontaneously form unless the p53 gene was 
simultaneously mutated [71].
After all, it would seem that the “cell-of-origin” 
concept for ES may turn out as too simplistic. EWSR1-
FLI1 may be fully transforming only cells that possess 
the right conditions, which are likely very limited 
during development. Such a narrow window of target 
cell emergence would explain the difficulty of inducing 
tumors in in vivo models. We suggest that RING1B is one 
defining epigenetic precondition for the oncogenic fusion 
to occur and, at least for some cases, reflects the cellular 
background of a hemato-endothelial precursor cell as the 
cell of origin.
MATERIALS AND METHODS
Study approval
A written informed consent was received from all 
patients prior to inclusion of their samples in the Hospital 
Sant Joan de Déu (HSJD) tumor biobank. Sixteen primary 
ES specimens were used in the study. Procedures were 
approved by the Ethical Committee for Clinical Research 
at HSJD.
Immunohistochemistry
Immunohistochemical analyses were performed 
following standard techniques [72]. RING1B and 
BMI1 antibodies were purchased from Millipore and 
EZH2 and MEL18 antibodies from Cell Signaling. 
Immunohistochemical staining was scored for staining 
intensity and proportion of stained cells by two 
independent investigators. A semiquantitative histoscore 
(0×% negative cells + 1×% weakly stained cells + 2×% 
moderately stained cells + 3×% strongly stained cells) was 
generated for statistical analysis. This histoscore thus has 
a range of possible scores between 0 and 300. Statistical 
analysis was performed with the Wilcoxon signed rank 
test.
Gene expression analysis
Microarray analysis, amplification, labeling and 
hybridizations were performed according to protocols 
from Ambion WT Expression Kit (Ambion), labeled 
using the WT Terminal Labeling Kit (Affymetrix), and 
then hybridized to GeneChip Human Gene 2.0 ST Array 
(Affymetrix).
Electrophysiology
Whole-cell voltage-clamp recordings from shMock 
and shRING1B ES1 cells were obtained using a D-6100 
Darmstadt amplifier (List Medical) filtered at 1 kHzand 
corrected for leak and capacitive currents using the leak 
subtraction procedure (P/8). Data are expressed as mean 
± SEM. For the generation of current-voltage (I-V) 
curves, peak inward Na+ currents were measured from 
cells clamped at -90 mV and pulsed for 40 ms from -65 
mV to +55 mV in 10 mV steps. Single I-V curves at each 
experimental condition were averaged to obtain the shown 
I-V curves.
Flow cytometry
Sub-G1population staining was performed as 
previously reported [73] and the analysis was performed 
by FACScan (Coulter).
Cell viability assay
Cells were seeded at 3000 per well in 96-well 
culture plates. S3I-201 (STAT3 inhibitor) was added to 
complete growth medium at concentrations ranging from 
1 to 200 μM, respectively. After 72 h, cells were subjected 
to the ATPlite assay (PerkinElmer, Waltham, MA, USA) 
and inhibitory concentrations were calculated.
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Statistics
Each experiment was performed in triplicate at 
least three times unless otherwise indicated. Statistical 
analysis was performed with Student’s t-test. P < 0.05 was 
considered significant.
Extended methods on cell culture, protein 
and mRNA analysis, gene expression arrays and 
electrophysiology are available as Supplemental 
Information.
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